BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 12735045)

  • 1. [Anticoagulant, antiplatelet agents].
    Ishikawa K
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():647-53. PubMed ID: 12735045
    [No Abstract]   [Full Text] [Related]  

  • 2. Is there less benefit from warfarin in diabetics after myocardial infarction? The numbing complexities of assessing anticoagulant and antiplatelet therapy in the diabetic patient.
    Smith DA
    Cardiology; 2008; 111(3):158-60. PubMed ID: 18434718
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiplatelet and anticoagulant therapy in acute myocardial infarction.
    Jafri SM
    Henry Ford Hosp Med J; 1991; 39(3-4):195-9. PubMed ID: 1804824
    [No Abstract]   [Full Text] [Related]  

  • 4. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
    Arjomand H; Cohen M; Ezekowitz MD
    J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations for peri-procedural thrombocyte aggregation inhibition].
    Sauer H; Leschke M
    Dtsch Med Wochenschr; 2006 Feb; 131(8):400-2. PubMed ID: 16479474
    [No Abstract]   [Full Text] [Related]  

  • 7. [Antiplatelet agents--problem for cardiac surgeon].
    Bochenek A; Wilczyński M
    Kardiol Pol; 2006 Nov; 64(11):1329-31. PubMed ID: 17165174
    [No Abstract]   [Full Text] [Related]  

  • 8. Outcomes associated with combined antiplatelet and anticoagulant therapy.
    Johnson SG; Rogers K; Delate T; Witt DM
    Chest; 2008 Apr; 133(4):948-54. PubMed ID: 18198244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
    Rubboli A; Halperin JL
    Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
    [No Abstract]   [Full Text] [Related]  

  • 11. [ASS plus dipyridamole or clopidogrel after stroke: what is the best secondary prevention?].
    Einecke D
    MMW Fortschr Med; 2008 May; 150(21):6-7. PubMed ID: 18575244
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiplatelet agents and arterial thrombosis.
    Billett HH
    Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 14. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
    Roldán V; Marín F
    Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
    [No Abstract]   [Full Text] [Related]  

  • 15. [Secondary stroke prevention according to the PRoFESS Study. What are the sequelae for practical therapy?].
    Diener C
    MMW Fortschr Med; 2008 May; 150(21):7. PubMed ID: 18578065
    [No Abstract]   [Full Text] [Related]  

  • 16. Reconsidering combined antiplatelet and anticoagulant therapy in atrial fibrillation.
    Falk RH
    J Am Coll Cardiol; 2004 Oct; 44(8):1567-9. PubMed ID: 15489086
    [No Abstract]   [Full Text] [Related]  

  • 17. Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
    Prescrire Int; 2009 Dec; 18(104):272-3. PubMed ID: 20027714
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.
    ; Anand S; Yusuf S; Xie C; Pogue J; Eikelboom J; Budaj A; Sussex B; Liu L; Guzman R; Cina C; Crowell R; Keltai M; Gosselin G
    N Engl J Med; 2007 Jul; 357(3):217-27. PubMed ID: 17634457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin, aspirin, or both after myocardial infarction.
    Pullicino P; Thompson JL
    N Engl J Med; 2003 Jan; 348(3):256-7; author reply 256-7. PubMed ID: 12529470
    [No Abstract]   [Full Text] [Related]  

  • 20. Antithrombotic therapy in heart failure.
    Verheugt FW
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):277-8. PubMed ID: 16716103
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.